PNC Financial Services Group’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-2,611
| Closed | -$14.8K | – | 5292 |
|
|
2025
Q3 | $14.8K | Buy |
2,611
+436
| +20% | +$2.23K | ﹤0.01% | 3772 |
|
|
2025
Q2 | $8.29K | Sell |
2,175
-1,014
| -32% | -$3.15K | ﹤0.01% | 3946 |
|
|
2025
Q1 | $8.39K | Buy |
3,189
+3,158
| +10,187% | +$10.3K | ﹤0.01% | 3890 |
|
|
2024
Q4 | $110 | Sell |
31
-61
| -66% | -$234 | ﹤0.01% | 4703 |
|
|
2024
Q3 | $420 | Hold |
92
| – | – | ﹤0.01% | 4586 |
|
|
2024
Q2 | $400 | Buy |
92
+64
| +229% | +$281 | ﹤0.01% | 4561 |
|
|
2024
Q1 | $141 | Buy |
28
+18
| +180% | +$101 | ﹤0.01% | 4632 |
|
|
2023
Q4 | $63 | Buy |
+10
| New | +$57 | ﹤0.01% | 4543 |
|
|
2023
Q3 | – | Sell |
-25,000
| Closed | -$255K | – | 4733 |
|
|
2023
Q2 | $255K | Buy |
+25,000
| New | +$261K | ﹤0.01% | 2035 |
|
|
2019
Q2 | – | Sell |
-118
| Closed | – | – | 4117 |
|
|
2019
Q1 | $0 | Hold |
118
| – | – | ﹤0.01% | 4123 |
|
|
2018
Q4 | $0 | Hold |
118
| – | – | ﹤0.01% | 4163 |
|
|
2018
Q3 | $0 | Hold |
118
| – | – | ﹤0.01% | 4225 |
|
|
2018
Q2 | $0 | Hold |
118
| – | – | ﹤0.01% | 4257 |
|
|
2018
Q1 | $2K | Buy |
+118
| New | +$1.59K | ﹤0.01% | 4056 |
|
PNC Financial Services Group's SCPH Position: Q4 2025 in Review
PNC Financial Services Group sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 2,611 shares — an estimated $14.8K sold.
PNC Financial Services Group first reported a position in SCPH in Q1 2018 and held it in 14 quarters. The position peaked at $255K in Q2 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- PNC Financial Services Group reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- PNC Financial Services Group sold 2,611 scPharmaceuticals shares in Q4 2025, an estimated $14.8K.
- PNC Financial Services Group first reported a position in scPharmaceuticals in Q1 2018 and held it in 14 quarters.
- PNC Financial Services Group's scPharmaceuticals position peaked at $255K in Q2 2023.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on PNC Financial Services Group's 13F filing for Q4 2025, filed 6 Feb 2026.